Cortisol and antidepressant effects of yoga

J Thirthalli, G H Naveen, M G Rao, S Varambally, R Christopher, B N Gangadhar, J Thirthalli, G H Naveen, M G Rao, S Varambally, R Christopher, B N Gangadhar

Abstract

Context: Hypercortisolemia is well-known in depression and yoga has been demonstrated earlier to reduce the parameters of stress, including cortisol levels.

Aim: We aimed to find the role of yoga as an antidepressant as well as its action on lowering the serum cortisol levels.

Settings and design: An open-labeled study consisting of three groups (yoga alone, yoga along with antidepressant medication and antidepressant medication alone) was conducted at a tertiary care psychiatry hospital.

Methodology: Out-patient depressives who were not suicidal were offered yoga as a possible antidepressant therapy. A validated yoga module was used as therapy taught over a month and to be practiced at home daily. Patients were free to choose the drugs if their psychiatrist advised. Patients (n=54) were rated on Hamilton Depression Rating Scale (HDRS) with serum cortisol measurements at baseline and after 3 months. In 54 patients, assessments and blood test results were both available. 19 each received yoga alone or with drugs and 16 received drugs only. Healthy comparison subjects (n=18) too underwent morning cortisol measurements once.

Results: Serum cortisol was higher in depressives compared with controls. In the total sample, the cortisol level dropped significantly at the end of treatment. More patients in the yoga groups had a drop in cortisol levels as compared to drug-only group. In the yoga-only group, the cortisol drop correlated with the drop in HDRS score (antidepressant effect).

Conclusion: The findings support that yoga may act at the level of the hypothalamus by its 'anti-stress' effects (reducing the cortisol), to bring about relief in depression.

Keywords: Cortisol; depression; hypercortisolemia; stress; yoga.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
The drop in depression scores correlated significantly with the drop in cortisol levels for yoga-only treatment group (n=19)
Figure 2
Figure 2
The change in hamilton depression rating scale scores in both cortisol-response groups

References

    1. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med. 2005;67(Suppl 1):S26–8.
    1. Christensen MV, Kessing LV. The hypothalamo-pituitary-adrenal axis in major affective disorder: A review. Nord J Psychiatry. 2001;55:359–63.
    1. Miller GE, Rohleder N, Stetler C, Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med. 2005;67:679–87.
    1. Raison CL, Miller AH. When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554–65.
    1. Janakiramaiah N, Gangadhar BN, Naga Venkatesha Murthy PJ, Harish MG, Subbakrishna DK, Vedamurthachar A. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: A randomized comparison with electroconvulsive therapy (ECT) and imipramine. J Affect Disord. 2000;57:255–9.
    1. Vedamurthachar A, Janakiramaiah N, Hegde JM, Shetty TK, Subbakrishna DK, Sureshbabu SV, et al. Antidepressant efficacy and hormonal effects of Sudarshana Kriya Yoga (SKY) in alcohol dependent individuals. J Affect Disord. 2006;94:249–53.
    1. American Psychiatric Association. Text Revision. 4th ed. Washington, DC: American Psychiatric Association; 2000. Diagnostic and Statistical Manual of Mental Disorders.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
    1. Schüle C, Baghai TC, Eser D, Zwanzger P, Jordan M, Buechs R, et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl) 2006;186:601–11.
    1. Hinkelmann K, Moritz S, Botzenhardt J, Muhtz C, Wiedemann K, Kellner M, et al. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: A longitudinal study. Psychoneuroendocrinology. 2012;37:685–92.
    1. Schüle C, Baghai T, Schmidbauer S, Bidlingmaier M, Strasburger CJ, Laakmann G. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology. 2004;29:185–200.
    1. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15:1768–77.
    1. Schaaf MJ, de Jong J, de Kloet ER, Vreugdenhil E. Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. Brain Res. 1998;813:112–20.
    1. Bravo JA, Díaz-Veliz G, Mora S, Ulloa JL, Berthoud VM, Morales P, et al. Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of neuroprotection. Behav Pharmacol. 2009;20:273–85.
    1. Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair NP, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci. 1998;1:69–73.
    1. Knoops AJ, Gerritsen L, van der Graaf Y, Mali WP, Geerlings MI. Basal hypothalamic pituitary adrenal axis activity and hippocampal volumes: The SMART-Medea study. Biol Psychiatry. 2010;67:1191–8.
    1. Gold SM, Kern KC, O’Connor MF, Montag MJ, Kim A, Yoo YS, et al. Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry. 2010;68:553–9.
    1. Mohandas E. Neurobiology of spirituality. Mens Sana Monogr. 2008;6:63–80.
    1. Renaud LP. CNS pathways mediating cardiovascular regulation of vasopressin. Clin Exp Pharmacol Physiol. 1996;23:157–60.
    1. Pietrowsky R, Braun D, Fehm HL, Pauschinger P, Born J. Vasopressin and oxytocin do not influence early sensory processing but affect mood and activation in man. Peptides. 1991;12:1385–91.
    1. Yadid G, Zangen A, Herzberg U, Nakash R, Sagen J. Alterations in endogenous brain beta-endorphin release by adrenal medullary transplants in the spinal cord. Neuropsychopharmacology. 2000;23:709–16.
    1. Janal MN, Colt EW, Clark WC, Glusman M. Pain sensitivity, mood and plasma endocrine levels in man following long-distance running: Effects of naloxone. Pain. 1984;19:13–25.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner